www.sec.gov/Archives/edgar/data/806592/...000026/suwn10-q.htm
Seite 20:
Recent Developments
Sunwin Stevia has approximately 1,200 metric tons of manufacturing capacity per year to produce high-grade stevia extract. With these manufacturing facilities, Sunwin Stevia is able to deliver stevia products containing Rebaudioside A in a range of 50% to 99% with a format of powder, granular, or tablet. We are planning to start building a new facility with annual capacity of 500 metric tons in order to meet substantially increased demand for our high-grade stevia products.
So sieht Zuversicht aus!
Nicht zu vergessen, man hat eine MEtformin Anlage gebaut, was laut den alten Berichten bei 1,1 Mio lag. Man hat die Anlage verpachtet und erhält ca. 437k$ Diese Zahl wird sich zum JAhresbericht dazu gesellen.
Since fiscal year 2018, we invested in a new production line for Metformin as one of the new product markets we intend to branch into. Metformin is the raw material of Metformin hydrochloride tablets. Metformin is the first-line medication for the treatment of type 2 diabetes, particularly in people who are not satisfied with simple diet control, especially those with obesity and hyperinsulinemia. This drug not only has hypoglycemic effect, but also may have the effect of reducing body weight and hyperinsulinemia. It can be effective in patients with poor efficacy of certain sulfonylureas, such as sulfonylureas, intestinal glycosidase inhibitors or thiazolidinedione hypoglycemic agents. It can also be used in patients with insulin therapy to reduce insulin consumption.
While we were able to market and sale our Metformin products, with our current overhead and associated expenses, its profit margin has not been as lucrative as we had projected, and our Metformin production line has been operating at a net loss in fiscal 2019. On July 10, 2019, we entered into a management agreement with Ru Yuan, an unaffiliated individual, to contract out the Metformin production line for 30 years. On July 31, 2019, we entered into an addendum to this agreement to include a renewal period of every 5 years. Under the terms of this agreement, Ms. Yuan will operate the Metformin production line independently from Sunwin assuming all of its profits and liabilities, including employee payroll, benefits, utilities etc., and will pay to Qufu Shengren an annual contract fee of RMB3,000,000 (approximately $436,047).
Zurück
Weiter
Werbung
